Morningstar

Pliant Therapeutics Inc Ordinary Shares PLRX

Morningstar Rating

Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer

GlobeNewswire Sep 24, 2024 12:00pm
Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Respiratory Society International Congress 2024

GlobeNewswire Sep 10, 2024 12:00pm
Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors

GlobeNewswire Aug 28, 2024 12:00pm
Pliant Therapeutics to Participate in Upcoming Investor Events

GlobeNewswire Aug 28, 2024 12:00pm
Pliant Therapeutics Announces Four Upcoming Presentations at the European Respiratory Society International Congress 2024

GlobeNewswire Aug 26, 2024 1:10pm
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results

GlobeNewswire Aug 7, 2024 8:05pm
Pliant Therapeutics to Participate in the Canaccord Genuity 44th Annual Growth Conference

GlobeNewswire Aug 6, 2024 8:03pm
Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-PSC Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Continued Antifibrotic and Anti-Cholestatic Activity Displayed Across Multiple Measures

GlobeNewswire Jul 15, 2024 12:00pm
Amazon and JPMorgan stocks fall, Rivian and DraftKings shares rally, and other stocks on the move

MarketWatch Sep 26, 2023 4:59pm
Pliant Therapeutics shares surge as liver-disease treatment shows promise in clinical trial

MarketWatch Sep 26, 2023 12:09pm

Sponsor Center

Transparency is our policy. Learn how it impacts everything we do

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

Verify your identity, personalize the content you receive, or create and administer your account.
Provide specific products and services to you, such as portfolio management or data aggregation.
Develop and improve features of our offerings.
Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.

© Copyright 2024 Morningstar, Inc. All rights reserved. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.